Vera Balz

Vera Balz

Auto-generated profile, based on publicly available information

Vera Balz

Institute of Experimental Medicine and Systems Biology, Medical Faculty, RWTH Aachen University, Aachen, Germany

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

29 November 2005 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
CGChristian Gwosdz
Christian Gwosdz
KSKathrin Scheckenbach
Kathrin Scheckenbach
OLOliver Lieven
Oliver Lieven
JRJulia Reifenberger
Julia Reifenberger
AKAndreas Knopf
Andreas Knopf
VBVera Balz
Vera Balz
The abrogation of the function of the “gatekeeper of the genome”, p53, is the most prevalent molecular alteration in solid human tumors. Regarding melanomas the involvement of p53 alterations is discussed controversially to date. In order to evaluate the status of p53 in detail, primary tumors and metastases of 63 sporadic cutaneous (CM) and mucosal (MuM) melanomas were examined by immunohistochemistry and sequence analysis of the entire coding region of the p53 transcript, i.e., exons 2 to 11. In addition, loss of heterozygosity (LOH) and loss of allele-specific transcription (LOT) were determined. Accumulation of the p53 protein occurred in most of the CM and MuM specimens (71% and 58%, respectively). In contrast, protein stabilizing p53 mutations were observed in 14% of the CM and no mutation was found in MuM specimens. Two of the aberrations located outside the core domain. LOH was detected in 22% CM and 58% MuM, and LOT in 25% of the CM specimens. The genotype distribution at the polymorphic p53 codon 72 in melanoma patients differed significantly from control subjects. The calculation of odds ratios (OR) and 95% confidence intervals (CI) indicated an increased risk for developing cutaneous melanomas in individuals carrying the Pro-coding allele. Altogether, aberrant p53 expression appears to be a common event in both CM and MuM.

16 December 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
FSFelix Schreibing
Felix Schreibing
MHMonica T. Hannani
Monica T. Hannani
HKHyojin Kim
Hyojin Kim
JNJames S. Nagai
James S. Nagai
FTFabio Ticconi
Fabio Ticconi
RKRafael Kramann
Rafael Kramann
Introduction: SARS-CoV-2 infection results in varying disease severity, ranging from asymptomatic infection to severe illness. A detailed understanding of the immune response to SARS-CoV-2 is critical to unravel the causative factors underlying differences in disease severity and to develop optimal vaccines against new SARS-CoV-2 variants.Methods: We combined single-cell RNA and T cell receptor sequencing with CITE-seq antibodies to characterize the CD8+ T cell response to SARS-CoV-2 infection at high resolution and compared responses between mild and severe COVID-19.Results: We observed increased CD8+ T cell exhaustion in severe SARS-CoV-2 infection and identified a population of NK-like, terminally differentiated CD8+ effector T cells characterized by expression of FCGR3A (encoding CD16). Further characterization of NK-like CD8+ T cells revealed heterogeneity among CD16+ NK-like CD8+ T cells and profound differences in cytotoxicity, exhaustion, and NK-like differentiation between mild and severe disease conditions.Discussion: We propose a model in which differences in the surrounding inflammatory milieu lead to crucial differences in NK-like differentiation of CD8+ effector T cells, ultimately resulting in the appearance of NK-like CD8+ T cell populations of different functionality and pathogenicity. Our in-depth characterization of the CD8+ T cell-mediated response to SARS-CoV-2 infection provides a basis for further investigation of the importance of NK-like CD8+ T cells in COVID-19 severity.

8 January 2018 in HLA
Verified
Journal Article
Closed access
PDF file
VBV. Balz
V. Balz
SKS. Krause
S. Krause
JFJ. Fischer
J. Fischer
JEJ. Enczmann
J. Enczmann

1 October 2002 in Cancer Genetics and Cytogenetics
Verified
Journal Article
Closed access
VBVera Balz
Vera Balz
HPHans Bernd Prisack
Hans Bernd Prisack
HBHenning Bier
Henning Bier
HBHans Bojar
Hans Bojar

1 November 2004 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
KSKathrin Scheckenbach
Kathrin Scheckenbach
OLOliver Lieven
Oliver Lieven
KGKarl Götte
Karl Götte
UBUlrike Bockmühl
Ulrike Bockmühl
RZRainer Zotz
Rainer Zotz
VBVera Balz
Vera Balz
A polymorphism at codon 72 of the human tumor suppressor p53 determines translation into either arginine or proline. Yet, the impact of this amino acid variability on the risk to develop malignant tumors, particularly carcinomas associated with human papilloma virus (HPV) infections, remains unresolved because of contradictory results. To address a potential correlation between the different genotypes and the manifestation of squamous cell carcinomas of the head and neck (SCCHN), we determined the p53 codon 72 in 193 healthy subjects and 122 unselected SCCHN with known HPV status. Furthermore, loss of allele-specific transcription was analyzed in p53 codon 72 heterozygous (Arg/Pro) SCCHN and correlated with HPV 16 and/or 18 E6 transcript expression. We found a moderately increased risk (odds ratio, 1.86; 95% confidence interval, 1.0-3.3) for individuals with germ line heterozygosity to develop SCC of the pharynx. On the other hand, p53 codon 72 polymorphic variants, most notably the Arg/Arg genotype, showed no association with the presence of HPV 16 and/or 18 E6 transcript. Moreover, there was no evidence for HPV-driven selection in SCCHN with allele-specific loss of transcription. Our data suggest that the p53 codon 72 polymorphism has a minor impact on the development of SCCHN.